Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Most of the melanoma markers used today are melanocytic markers or pigmentation pathway-associated genes driven by the microphthalmia transcription factor, MITF, and include among others, tyrosinase, dopachrome tautomerase, DCT, melan-A and S100B. Genomic studies repeatedly revealed several novel melanoma marker genes including those of the transcription factor NOTCH2, WNT5A, proliferation-associated genes TOPO2A and CDC2, membrane receptors FGFR and EphA3, adhesion molecules N-cadherin, β3 integrin and syndecan-4, and the cell surface antigens CD59/protectin and MIA. Other genomic analyses tried to define the gene signature of the metastatic disease but failed to find a consistent one except the gold standard genes of β3 integrin, syndecan-4 and WNT5a. Studies on the gene signatures of chemoresistance and cytokine sensitivity of melanoma clearly defined apoptosis-resistance as one of the key elements of the above biological properties, but the data are controversial, mostly because of the use of inappropriate model systems and the lack of confirmation on clinical samples. Accordingly, application of genomic technologies must be more "translational" to provide breakthrough in melanoma diagnosis and therapy.

Original languageEnglish
Pages (from-to)154-157
Number of pages4
JournalCellular Immunology
Volume244
Issue number2
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Genomics
Melanoma
Syndecan-4
Microphthalmia-Associated Transcription Factor
Genes
Cadherins
EphA3 Receptor
Integrins
Therapeutics
CD59 Antigens
MART-1 Antigen
Monophenol Monooxygenase
Pigmentation
Surface Antigens
Transcription Factors
Apoptosis
Cytokines
Technology
Membranes

Keywords

  • Cytokine therapy
  • Genomics
  • Melanoma
  • Metastasis

ASJC Scopus subject areas

  • Cell Biology
  • Immunology

Cite this

Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies. / Tímár, J.; Mészáros, L.; Ladányi, A.; Puskás, L.; Rásó, E.

In: Cellular Immunology, Vol. 244, No. 2, 12.2006, p. 154-157.

Research output: Contribution to journalArticle

@article{b761e908db85409b9eb8deb91b0177f6,
title = "Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies",
abstract = "Most of the melanoma markers used today are melanocytic markers or pigmentation pathway-associated genes driven by the microphthalmia transcription factor, MITF, and include among others, tyrosinase, dopachrome tautomerase, DCT, melan-A and S100B. Genomic studies repeatedly revealed several novel melanoma marker genes including those of the transcription factor NOTCH2, WNT5A, proliferation-associated genes TOPO2A and CDC2, membrane receptors FGFR and EphA3, adhesion molecules N-cadherin, β3 integrin and syndecan-4, and the cell surface antigens CD59/protectin and MIA. Other genomic analyses tried to define the gene signature of the metastatic disease but failed to find a consistent one except the gold standard genes of β3 integrin, syndecan-4 and WNT5a. Studies on the gene signatures of chemoresistance and cytokine sensitivity of melanoma clearly defined apoptosis-resistance as one of the key elements of the above biological properties, but the data are controversial, mostly because of the use of inappropriate model systems and the lack of confirmation on clinical samples. Accordingly, application of genomic technologies must be more {"}translational{"} to provide breakthrough in melanoma diagnosis and therapy.",
keywords = "Cytokine therapy, Genomics, Melanoma, Metastasis",
author = "J. T{\'i}m{\'a}r and L. M{\'e}sz{\'a}ros and A. Lad{\'a}nyi and L. Pusk{\'a}s and E. R{\'a}s{\'o}",
year = "2006",
month = "12",
doi = "10.1016/j.cellimm.2006.12.009",
language = "English",
volume = "244",
pages = "154--157",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies

AU - Tímár, J.

AU - Mészáros, L.

AU - Ladányi, A.

AU - Puskás, L.

AU - Rásó, E.

PY - 2006/12

Y1 - 2006/12

N2 - Most of the melanoma markers used today are melanocytic markers or pigmentation pathway-associated genes driven by the microphthalmia transcription factor, MITF, and include among others, tyrosinase, dopachrome tautomerase, DCT, melan-A and S100B. Genomic studies repeatedly revealed several novel melanoma marker genes including those of the transcription factor NOTCH2, WNT5A, proliferation-associated genes TOPO2A and CDC2, membrane receptors FGFR and EphA3, adhesion molecules N-cadherin, β3 integrin and syndecan-4, and the cell surface antigens CD59/protectin and MIA. Other genomic analyses tried to define the gene signature of the metastatic disease but failed to find a consistent one except the gold standard genes of β3 integrin, syndecan-4 and WNT5a. Studies on the gene signatures of chemoresistance and cytokine sensitivity of melanoma clearly defined apoptosis-resistance as one of the key elements of the above biological properties, but the data are controversial, mostly because of the use of inappropriate model systems and the lack of confirmation on clinical samples. Accordingly, application of genomic technologies must be more "translational" to provide breakthrough in melanoma diagnosis and therapy.

AB - Most of the melanoma markers used today are melanocytic markers or pigmentation pathway-associated genes driven by the microphthalmia transcription factor, MITF, and include among others, tyrosinase, dopachrome tautomerase, DCT, melan-A and S100B. Genomic studies repeatedly revealed several novel melanoma marker genes including those of the transcription factor NOTCH2, WNT5A, proliferation-associated genes TOPO2A and CDC2, membrane receptors FGFR and EphA3, adhesion molecules N-cadherin, β3 integrin and syndecan-4, and the cell surface antigens CD59/protectin and MIA. Other genomic analyses tried to define the gene signature of the metastatic disease but failed to find a consistent one except the gold standard genes of β3 integrin, syndecan-4 and WNT5a. Studies on the gene signatures of chemoresistance and cytokine sensitivity of melanoma clearly defined apoptosis-resistance as one of the key elements of the above biological properties, but the data are controversial, mostly because of the use of inappropriate model systems and the lack of confirmation on clinical samples. Accordingly, application of genomic technologies must be more "translational" to provide breakthrough in melanoma diagnosis and therapy.

KW - Cytokine therapy

KW - Genomics

KW - Melanoma

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=34248359385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248359385&partnerID=8YFLogxK

U2 - 10.1016/j.cellimm.2006.12.009

DO - 10.1016/j.cellimm.2006.12.009

M3 - Article

C2 - 17433276

AN - SCOPUS:34248359385

VL - 244

SP - 154

EP - 157

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 2

ER -